Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Manoop S. Bhutani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1489-5947; OpenAlex author ID A5057774493, A5060681029, A5087233695. Sources: ClinicalTrials.gov.

Their work

Papers
45 (first author 2, last author 10)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
184
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: 1 paper, 1 trial · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 5 papers · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 45

  1. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Co-author DOI 10.1055/a-2733-1068↗
  2. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-3189↗
  3. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  4. Fatty pancreas on EUS: Risk factors, correlation with CT/MRI, and implications for pancreatic cancer screening. Last author DOI 10.1097/eus.0000000000000109↗
  5. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  6. Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals: an opportunity not to be missed Co-author DOI 10.1016/j.gie.2024.12.001↗
  7. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients wit… Co-author DOI 10.1016/j.prro.2023.11.011↗
  8. Comments and illustrations of the European Federation of Societies for Ultrasound in Medicine contrast-enhanced ultrasound guidelines. Rare pancreatic tumors, … Co-author DOI 10.1097/eus.0000000000000056↗
  9. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  10. Bacterial and fungal characterization of pancreatic adenocarcinoma from Endoscopic Ultrasound-guided biopsies. Co-author DOI 10.3389/fimmu.2023.1268376↗
  11. Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer. Last author DOI 10.3390/cancers15225355↗
  12. Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB. Co-author DOI 10.1002/cncy.22533↗
  13. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  14. Precision Oncology With Germline and Somatic Sequencing in Pancreatic Cancer: The Time Is Now. Last author DOI 10.1097/mpa.0000000000002026↗
  15. Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using pe… Co-author DOI 10.11152/mu-3503↗
  16. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  17. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2020.11.006↗
  18. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite … Co-author DOI 10.1016/j.ctro.2021.02.004↗
  19. Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. Co-author DOI 10.1158/1078-0432.ccr-20-2667↗
  20. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Co-author DOI 10.1158/1078-0432.ccr-20-3925↗
  21. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Co-author DOI 10.4103/eus-d-20-00230↗
  22. Endoscopic Ultrasound-Guided Treatment of Pancreatic Cancer. Last author DOI 10.1007/s11894-020-00767-1↗
  23. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
  24. Upfront molecular profiling of pancreatic cancer patients - An idea whose time has come. Co-author DOI 10.1016/j.pan.2020.01.017↗
  25. Permanent endoscopic reversal of Roux-en-Y gastric bypass for diagnosis and long-term palliation of pancreatic cancer. Co-author DOI 10.1016/j.vgie.2020.04.017↗
  26. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  27. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Co-author DOI 10.4103/eus.eus_56_19↗
  28. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  29. EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. Last author DOI 10.1016/j.vgie.2019.05.007↗
  30. Pancreatic Cancer Early Detection and Interception in an Atypical Case of Peutz-Jeghers Syndrome Co-author DOI 10.1097/mpa.0000000000001293↗
  31. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic canc… Co-author DOI 10.4103/eus.eus_16_19↗
  32. Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: A systematic review. Co-author DOI 10.4103/eus.eus_25_18↗
  33. Pancreatic cancer screening in high-risk individuals with germline genetic mutations. Co-author DOI 10.1016/j.gie.2017.12.019↗
  34. A Diagnostic Challenge: Pancreatic Cancer or Autoimmune Pancreatitis? Last author DOI 10.12865/chsj.44.02.15↗
  35. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  36. Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. Last author PMID 28656024↗
  37. The role of endoscopic ultrasound in pancreatic cancer screening. Co-author DOI 10.4103/2303-9027.175876↗
  38. The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. Last author DOI 10.4103/2303-9027.190932↗
  39. Differentiation of pancreatic ductal adenocarcinoma from other neoplastic solid pancreatic lesions: a tertiary oncology center experience. Co-author DOI 10.1016/j.gie.2014.08.023↗
  40. Preparation and evaluation of polyethyleneimine-single walled carbon nanotube conjugates as vectors for pancreatic cancer treatment. Co-author DOI 10.1039/c4tb00778f↗
  41. Pancreatic Cancer Screening: What We Do and Do Not Know Co-author DOI 10.1016/j.cgh.2013.02.004↗
  42. Endoscopic ultrasound-guided oncologic therapy for pancreatic cancer. Last author DOI 10.1155/2013/157581↗
  43. Feasibility study of EUS-NOTES as a novel approach for pancreatic cancer staging and therapy: an international collaborative study. First author DOI 10.5754/hge11774↗
  44. Endoscopic ultrasound-guided radiation therapy in pancreatic cancer. First author PMID 24212355↗
  45. Pancreatic cancer: early detection, diagnosis, and screening. Last author DOI 10.1007/s12328-012-0327-0↗

Trials 1

  1. Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions Principal investigator NCT02494388↗

Closest collaborators

The 25 strongest of 184 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Irina Mihaela Cazacu · 13 shared papers, 2019–2025 · strength 1.77
  2. Eugene Jon Koay · 12 shared papers, 2017–2025 · strength 1.46
  3. Anirban Maitra · 11 shared papers, 2017–2025 · strength 1.30
  4. Matthew H. G. Katz · 11 shared papers, 2013–2025 · strength 1.25
  5. Florencia M. McAllister · 7 shared papers, 2017–2025 · strength 1.14
  6. Adrian Săftoiu · 9 shared papers, 2013–2025 · strength 1.07
  7. Cullen M. Taniguchi · 9 shared papers, 2019–2023 · strength 0.99
  8. Joseph M. Herman · 8 shared papers, 2019–2024 · strength 0.94
  9. Albert C. Koong · 6 shared papers, 2019–2025 · strength 0.74
  10. Robert A. Wolff · 7 shared papers, 2017–2025 · strength 0.73
  11. Michael P. Kim · 5 shared papers, 2017–2025 · strength 0.72
  12. Brian R. Weston · 7 shared papers, 2017–2022 · strength 0.70
  13. Ching-Wei David Tzeng · 6 shared papers, 2019–2025 · strength 0.69
  14. Shubham Pant · 5 shared papers, 2019–2023 · strength 0.66
  15. Jeffrey H. Lee · 7 shared papers, 2013–2022 · strength 0.56
  16. Emmanuel S. Coronel · 5 shared papers, 2018–2022 · strength 0.52
  17. Vincent Bernard · 4 shared papers, 2021–2025 · strength 0.52
  18. Ethan Bernard Ludmir · 3 shared papers, 2022–2025 · strength 0.42
  19. Shalini Moningi · 4 shared papers, 2019–2023 · strength 0.41
  20. Maureen E. Mork · 2 shared papers, 2019–2024 · strength 0.41
  21. Eileen Mary O'Reilly · 2 shared papers, 2025–2026 · strength 0.37
  22. Naruhiko Ikoma · 3 shared papers, 2020–2022 · strength 0.37
  23. Manisha Palta · 3 shared papers, 2020–2025 · strength 0.36
  24. Jason B. Fleming · 5 shared papers, 2013–2022 · strength 0.33
  25. John Raymond Zalcberg · 2 shared papers, 2021–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.